Trimbow 87 micrograms/5 micrograms/9 micrograms pressurised inhalation

A Phase II, multinational, multicentre, double-blind, randomised, active-controlled, 3-way cross-over study to evaluate the therapeutic equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a versus CHF5993 pMDI 100/6/12.5 µg HFA-134a in subjects with mild to moderate asthma. [TRECONY]

Symptoms control and adhErenCe assessment during treatment with mepolizUmab new pREfilled devices. SECURE